Premium
Prognostic value of the proliferation‐related antigen Ki‐67 in oligodendrogliomas
Author(s) -
Kros Johan M.,
Hop Wim C. J.,
Godschalk Josiane J. C. J.,
Krishnadath Kausilia K.
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960901)78:5<1107::aid-cncr22>3.0.co;2-5
Subject(s) - grading (engineering) , medicine , multivariate analysis , oncology , antigen , mitotic index , ki 67 , pathology , immunohistochemistry , immunology , mitosis , biology , ecology , microbiology and biotechnology
BACKGROUND In various neoplasms expression of the proliferation‐related Ki‐67 antigen has successfully been linked with parameters of progression of disease. While a definite grading scheme for oligodendrogliomas has still not been agreed upon, any parameter of tumor proliferation that might be helpful in predicting clinical outcome should be evaluated. METHODS The expression of the proliferation related nuclear antigen Ki‐67 (MIB‐1 monoclonal antibody) was investigated in a series of 108 verified oligodendrogliomas, and the percentages of immunoreactive cells were compared with the survival times of the patients. Using multivariate analysis the prognostic value of MIB‐1 labeling index (LI) was assessed taking into account age, tumor site, grade, and mitotic index (MI). RESULTS Patient's age, tumor site, grading according to the grading scheme by Smith, MI and MIB‐1 LI were all significantly related to survival. Whereas in a multivariate analysis, age, site, grade and MIB‐1 LI had independent prognostic significance, MI failed to add significant prognostic value. CONCLUSIONS The MIB‐1 LI is an important addition to histopathologic grading for predicting clinical outcome of patients with oligodendrogliomas. The MIB‐1 LI adds prognostic information independent of patient's age, tumor site and grade. The MI might be incorporated into a grading scheme for oligodendrogliomas, but is not by itself an additional prognosticator. Cancer 1996;78:1107‐13.